Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
| In millions, except per share items | Apr-25-14 | Apr-26-13 | Apr-27-12 | Apr-29-11 | Apr-30-10 | Apr-24-09 | Apr-25-08 | Apr-24-07 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Cardiac and Vascular Group | 8,847.0 | 8,695.0 | 8,482.0 | 8,119.0 | 8,132.0 | | 7,423.0 | 7,170.0 |
| Restorative Therapies Group | 6,501.0 | 6,369.0 | 6,221.0 | 7,389.0 | 7,260.0 | | 6,092.0 | 5,129.0 |
| Diabetes Group | 1,526.0 | 1,481.0 | 1,481.0 | | | | | |
| Other | 131.0 | 45.0 | | | | | | |
| Total revenues | 17,005.0 | 16,590.0 | 16,184.0 | 15,508.0 | 15,392.0 | 14,599.0 | 13,515.0 | 12,299.0 |
| Revenue growth [+] | 2.5% | 2.5% | 4.4% | 0.8% | 5.4% | 8.0% | 9.9% | 8.9% |
| Cardiac and Vascular Group | 1.7% | 2.5% | 4.5% | -0.2% | | | 3.5% | 5.3% |
| Restorative Therapies Group | 2.1% | 2.4% | -15.8% | 1.8% | | | 18.8% | 14.4% |
| Diabetes Group | 3.0% | 0.0% | | | | | | |
| Cost of goods sold | 4,333.0 | 4,126.0 | 3,889.0 | 3,700.0 | 3,582.0 | 3,518.0 | 3,446.0 | 3,168.0 |
| Gross profit | 12,672.0 | 12,464.0 | 12,295.0 | 11,808.0 | 11,810.0 | 11,081.0 | 10,069.0 | 9,131.0 |
| Gross margin | 74.5% | 75.1% | 76.0% | 76.1% | 76.7% | 75.9% | 74.5% | 74.2% |
| Selling, general and administrative | 5,847.0 | 5,698.0 | 5,623.0 | 5,427.0 | 5,282.0 | 5,152.0 | 4,707.0 | 4,153.0 |
| Research and development | 1,477.0 | 1,557.0 | 1,490.0 | 1,472.0 | 1,424.0 | 1,355.0 | 1,275.0 | 1,239.0 |
| Other operating expenses | 1,417.0 | 635.0 | 801.0 | 463.0 | 490.0 | 1,731.0 | 1,192.0 | 322.0 |
| EBITDA [+] | 4,781.0 | 5,393.0 | 5,214.0 | 5,250.0 | 5,386.0 | 3,542.0 | 3,532.0 | 4,000.0 |
| EBITDA growth | -11.3% | 3.4% | -0.7% | -2.5% | 52.1% | 0.3% | -11.7% | 0.5% |
| EBITDA margin | 28.1% | 32.5% | 32.2% | 33.9% | 35.0% | 24.3% | 26.1% | 32.5% |
| Depreciation | 501.0 | 488.0 | 498.0 | 465.0 | 455.0 | 418.0 | 637.0 | 583.0 |
| EBITA | 4,280.0 | 4,905.0 | 4,716.0 | 4,785.0 | 4,931.0 | 3,124.0 | 2,895.0 | 3,417.0 |
| EBITA margin | 25.2% | 29.6% | 29.1% | 30.9% | 32.0% | 21.4% | 21.4% | 27.8% |
| Amortization of intangibles | 349.0 | 331.0 | 335.0 | 339.0 | 317.0 | 281.0 | | |
| EBIT [+] | 3,931.0 | 4,574.0 | 4,381.0 | 4,446.0 | 4,614.0 | 2,843.0 | 2,895.0 | 3,417.0 |
| EBIT growth | -14.1% | 4.4% | -1.5% | -3.6% | 62.3% | -1.8% | -15.3% | -0.6% |
| EBIT margin | 23.1% | 27.6% | 27.1% | 28.7% | 30.0% | 19.5% | 21.4% | 27.8% |
| Non-recurring items [+] | 118.0 | 172.0 | 87.0 | 504.0 | 424.0 | 220.0 | 119.0 | 28.0 |
| Unusual expense | 40.0 | | | | | 100.0 | 78.0 | |
| Interest expense, net [+] | 108.0 | 151.0 | 149.0 | 278.0 | 246.0 | 183.0 | 36.0 | -154.0 |
| Interest expense | 108.0 | 151.0 | 149.0 | 278.0 | 246.0 | 183.0 | 36.0 | |
| Interest income | | | | | | | | 154.0 |
| Other income (expense), net | | | | | | | | -28.0 |
| Pre-tax income | 3,705.0 | 4,251.0 | 4,145.0 | 3,664.0 | 3,944.0 | 2,440.0 | 2,740.0 | 3,515.0 |
| Income taxes | 640.0 | 784.0 | 730.0 | 609.0 | 861.0 | 370.0 | 602.0 | 713.0 |
| Tax rate | 17.3% | 18.4% | 17.6% | 16.6% | 21.8% | 15.2% | 22.0% | 20.3% |
| Earnings from continuing ops | 3,065.0 | 3,467.0 | 3,009.0 | 3,014.0 | 3,067.0 | 2,070.0 | 2,138.0 | 2,802.0 |
| Earnings from discontinued ops | | | 406.0 | 41.0 | 16.0 | | | |
| Net income | 3,065.0 | 3,467.0 | 3,415.0 | 3,055.0 | 3,083.0 | 2,070.0 | 2,138.0 | 2,802.0 |
| Net margin | 18.0% | 20.9% | 21.1% | 19.7% | 20.0% | 14.2% | 15.8% | 22.8% |
| |
| Basic EPS [+] | $3.06 | $3.40 | $2.86 | $2.80 | $2.77 | $1.85 | $1.89 | $2.44 |
| Growth | -10.1% | 19.1% | 2.1% | 0.9% | 50.3% | -2.2% | -22.6% | 15.3% |
| Diluted EPS [+] | $3.02 | $3.37 | $2.84 | $2.79 | $2.76 | $1.84 | $1.87 | $2.41 |
| Growth | -10.4% | 18.9% | 1.9% | 0.8% | 50.4% | -1.7% | -22.5% | 15.3% |
| |
| Dividends per share [+] | $1.12 | $1.04 | $0.97 | $0.90 | $0.82 | $0.75 | $0.50 | |
| Growth | 7.7% | 7.2% | 7.8% | 9.8% | 9.3% | 50.0% | | |
| |
| Shares outstanding (basic) [+] | 1,002.1 | 1,019.3 | 1,053.9 | 1,077.4 | 1,106.3 | 1,121.9 | 1,133.0 | 1,149.7 |
| Growth | -1.7% | -3.3% | -2.2% | -2.6% | -1.4% | -1.0% | -1.5% | -4.5% |
| Shares outstanding (diluted) [+] | 1,013.6 | 1,027.5 | 1,059.9 | 1,081.7 | 1,109.4 | 1,126.3 | 1,143.8 | 1,161.8 |
| Growth | -1.4% | -3.1% | -2.0% | -2.5% | -1.5% | -1.5% | -1.5% | -4.6% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|